Traitements5programmes
Essais4liés
Publications4liées
SourceDBlocale

Traitements

5
MoléculeIndication / populationPhaseObjectifPaysRésultat
TelitaciceptThis is a multi-center, open-label, phase I study. Lupus, Myasthénie Non applicable À vérifier China À vérifier
TelitaciceptThis is a multi-center, open-label, phase I study. Lupus Phase 1 À vérifier China À vérifier
TelitaciceptThis is a multi-center, open-label, phase I study. Myasthénie Phase 3 À vérifier United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Georgia, Italy, Japan, Poland, Spain À vérifier
TelitaciceptThis is a multi-center, open-label, phase I study. Myasthénie Phase 3 À vérifier China À vérifier
TelitaciceptThis is a multi-center, open-label, phase I study. Myasthénie Non applicable À vérifier China À vérifier

Essais cliniques

4
MoléculeIndication / populationPhaseNCTTitreStatut
Telitacicept Myasthénie Non applicable NCT07298928 A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis NOT_YET_RECRUITING
Telitacicept Myasthénie Phase 3 NCT07249632 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) RECRUITING
Telitacicept Myasthénie Phase 3 NCT06456580 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) RECRUITING
Telitacicept Lupus Phase 1 NCT05247203 Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus COMPLETED

Publications

4
MoléculeIndication / populationTitreJournalDate
Telitacicept Comparative effectiveness and predictors of SRI-4 and LLDAS attainment in active systemic lupus erythematosus: a real-world study of telitacicept versus belimumab. Clinical rheumatology
Telitacicept Research on the safety and efficacy of telitacicept in the treatment of IgA nephropathy in children. Renal failure
Telitacicept Case Report: Telitacicept in the treatment of refractory juvenile idiopathic arthritis: clinical experience from three cases. Frontiers in pediatrics
Telitacicept Efficacy and safety of BAFF/APRIL-pathway inhibitors versus placebo in adults with IgA nephropathy: a systematic review with pairwise and network meta-analysis. BMC nephrology